Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O14662
UPID:
STX16_HUMAN
Alternative names:
-
Alternative UPACC:
O14662; A6NK32; A6NN69; A8MPP0; B7ZBN1; B7ZBN2; B7ZBN3; E1P5M0; E1P607; O14661; O14663; O60517; Q5W084; Q5W086; Q5W087; Q5XKI6; Q6GMS8; Q9H0Z0; Q9H1T7; Q9H1T8; Q9UIX5
Background:
Syntaxin-16, a SNARE protein, plays a crucial role in vesicular transport from the late endosomes to the trans-Golgi network. Its precise function and structure are key to understanding intracellular trafficking processes.
Therapeutic significance:
The involvement of Syntaxin-16 in Pseudohypoparathyroidism 1B, a disorder marked by resistance to parathyroid hormone, highlights its potential as a therapeutic target. Understanding the role of Syntaxin-16 could open doors to potential therapeutic strategies.